-
We face a new scientific challenge: how to demonstrate the
safety and efficacy of promising new antiretroviral drugs when the two
traditional study designs – the superiority trial and the
non-inferiority trial – are no longer useful in showing improvements in
both “treatment experienced” patients and those who have never received
drug therapy (treatment-naïve patients).
07 February 2012 | Forum for Collaborative HIV Research
-
Gilead Sciences Inc. (Nasdaq: GILD) today announced the start of a Phase II clinical trial to evaluate a modified version of its experimental “quad” fixed-dose combination (FDC) tablet currently being reviewed by the U.S. Food and Drug Administration, according to a company announcement.
30 January 2012 | AIDSMeds
-
The Phase 2 study will evaluate GS-7340 as part of a once-daily,
co-formulated single-tablet regimen that will also contain the boosting
agent cobicistat, the integrase inhibitor elvitegravir, and Emtriva(R)
(emtricitabine). The GS-7340-containing single-tablet regimen will be
compared to Gilead's Quad single-tablet regimen, which contains Viread
and Emtriva (as Truvada(R)), elvitegravir and cobicistat, and
is currently under review for marketing approval by U.S. and European
regulatory agencies.
24 January 2012 | Gilead press release
-
In perhaps the most comprehensive survey of the inner workings of HIV, an international team of scientists led by researchers at the University of California, San Francisco has mapped every apparent physical interaction the virus makes with components of the human cells it
infects—work that may reveal new ways to design future HIV/AIDS drugs.
21 December 2011 | UCSF Today
-
Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the Marketing
Authorisation Application (MAA) for the Quad single-tablet regimen of
elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
fumarate for the treatment of HIV-1 infection in adults, submitted on
November 24, 2011, has been validated by the European Medicines Agency
(EMA).
21 December 2011 | Gilead press release
-
Gilead Sciences (GILD) has a current portfolio dominated by HIV treatment drugs. More than 70% of its sales come from HIV treatment products. However it also discovers, develops, and commercializes treatments for other infectious and pulmonary diseases.
20 December 2011 | Seeking Alpha
-
Researchers are working to find out whether a HIV vaccine developed by a Norwegian biotech company can be administered nasally.
19 December 2011 | Health Canal
-
Raleigh, North Carolina-based Salix Pharmaceuticals announced
on Tuesday, December 14, that it has submitted a New Drug Application
(NDA) to the U.S. Food and Drug Administration (FDA) requesting approved
for Crofelemer, a novel therapy for HIV-associated diarrhea.
15 December 2011 | AIDSMeds.com
-
Aethlon Medical, the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS).
15 December 2011 | PR Newswire (press release)
-
Company to Submit U.S. Regulatory Filing for Elvitegravir in Second Quarter of 2012
09 December 2011 | Market Watch
Talking points: a checklist for you and your doctorTalking points is designed to help you talk to your doctor about HIV
treatment.
Preventing HIVAn essential resource providing evidence-based information on preventing HIV infection. 
HIV treatment update – Winter 201206 February 2012The new edition of HIV treatment update (HTU) is now...
A visit from Wandsworth Oasis26 January 2012On Wednesday this
week, we were delighted to have a visit...
Adventurers with HIV – a photo gallery19 January 2012Back in
November we sent out a
call for adventurous people with...